Exceptional Response to Trastuzumab Deruxtecan in a Patient With Recurrent Ovarian Clear Cell Carcinoma With Human Epidermal Growth Factor Receptor 2 Expression

Kong, Ben L.; Stommel, Jayne M.; Keck, Jamie M.; Kilburn, David; Streblow, Aaron; Egger, Julian; Creason, Allison L.; Suciu, Christopher G.; Guimaraes, Alexander R.; Corless, Christopher L.; Mills, Gordon B.; Pejovic, Tanja B.

doi:10.1200/po.23.00686

JCO Precis Oncol

2024

DOI: 10.1200/po.23.00686

|View full text |Cite

Exceptional Response to Trastuzumab Deruxtecan in a Patient With Recurrent Ovarian Clear Cell Carcinoma With Human Epidermal Growth Factor Receptor 2 Expression

Ben L. Kong,

Jayne M. Stommel,

Jamie M. Keck

et al.

Abstract: Case report of a HER2-expressed ovarian clear cell carcinoma with exceptional response to trastuzumab deruxtecan.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Ovarian clear cell carcinoma: research progress in oncogenesis and novel therapeutic strategies

Duan,

Sun,

Chen

et al. 2024

Academia Oncology

View full text Add to dashboard Cite

Ovarian clear cell carcinoma: research progress in oncogenesis and novel therapeutic strategies

Duan,

Sun,

Chen

et al. 2024

Academia Oncology

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Exceptional Response to Trastuzumab Deruxtecan in a Patient With Recurrent Ovarian Clear Cell Carcinoma With Human Epidermal Growth Factor Receptor 2 Expression

Abstract: Case report of a HER2-expressed ovarian clear cell carcinoma with exceptional response to trastuzumab deruxtecan.

Cited by 1 publication

References 16 publications

Ovarian clear cell carcinoma: research progress in oncogenesis and novel therapeutic strategies

Ovarian clear cell carcinoma: research progress in oncogenesis and novel therapeutic strategies

Contact Info

Product

Resources

About